Funding
← Back to your selection

Janus Henderson Investors

Activity from announced rounds

Activity in this selectionOct 18, 2026 · Jul 21, 2026

Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.

Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.

The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.

Sources
Rounds participated in
5
Confirmed lead rounds
0
1 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$1.6B
5 disclosed · full round size, not this investor’s share

By stage

Series C+4
Series B1

By primary sector

Biotech4
Climate tech1

By country

United States3
1
United Kingdom1

Rounds

5 in this selection
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Participant
FORM ENERGY

Long-duration iron-air batteries designed to store electricity for multi-day grid needs.

$750MSeries G
Participant